semaglutide news today october 2025 Novo Nordisk gears up for December Ozempic launch in India, sources say Majority of adults with obesity

While the development of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has expanded diabetes care, the bulk of the literature on these medications derives from tightly controlled clinical trials (e.g., Phase III trials such as the global PIONEER program), with only a few studies investigating their real-world effectiveness

The information we publish is educational only and based on our opinions plus our models

Some people call it microdosing, that term

GLP-1 increases insulin secretion and synthesis as well as increases insulin sensitivity, induces beta cell growth, and inhibits glucagon secretion (1)

And, it must eliminate the use of vague and unavailing plan terms that lead not only to confusion, but to management and compliance failures